Growth Trial: Study of the Renata Minima Stent

Inclusion criteria include: * The subject's legally authorized representative has been informed of the nature of the clinical investigation, agrees to its provisions, and has provided written informed consent * Requiring treatment\* of: * native, acquired, or recurrent aortic coarctation, or * native, acquired, or recurrent pulmonary artery stenosis \*As defined by the patient's medical team * Patency of at least one femoral vein, femoral artery, jugular vein or both carotid arteries able to accommodate the delivery system * Adjacent vessel to stenosis measuring \> or equal to 4 mm Exclusion criteria include: * Active bloodstream infection requiring antibiotic therapy within 3 days prior to stent implantation * History of or active endocarditis (active treatment with antibiotics) within 180 days prior to stent implantation * Aortic or pulmonary artery aneurysm in the location targeted for treatment * Body weight \< 1.5 kg * Anatomic location of lesion judged by the investigator to not lend to the safe placement of a stent * Target vessels larger or smaller than the Minima System balloon size ranges * Known genetic syndrome known to be associated with vasculopathies such as but not limited to Williams syndrome, Loeys-Dietz syndrome, etc * Clinical scenario requiring that more than one vessel needs stent implantation at the time of the trial procedure. * Currently participating in an investigational drug study or another device study * Major or progressive non-cardiac disease resulting in a life expectancy of less than six months * Known hypersensitivity to aspirin or heparin and cannot be treated with other antiplatelet and/or antithrombotic medications * Known hypersensitivity to cobalt-chromium or contrast media that cannot be adequately pre-medicated